<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="39867">Valproic acid</z:chebi> (VPA) has been shown to inhibit <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase activity and to synergize with <z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) in the differentiation induction of <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) blasts in vitro </plain></SENT>
<SENT sid="1" pm="."><plain>We treated 18 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> secondary to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (sAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with VPA monotherapy (serum concentrations 346-693 microM [50-100 microg/mL]) </plain></SENT>
<SENT sid="2" pm="."><plain>Five patients received VPA and ATRA (80 mg/m(2)/d, days 1-7, every other week) </plain></SENT>
<SENT sid="3" pm="."><plain>Response according to international working group (IWG) criteria was observed in 8 patients (44%) on VPA monotherapy, including 1 partial remission </plain></SENT>
<SENT sid="4" pm="."><plain>Median response duration was 4 months (range, 3-9 months) </plain></SENT>
<SENT sid="5" pm="."><plain>Four of 5 patients relapsing were treated with VPA + ATRA, 2 of them responding again </plain></SENT>
<SENT sid="6" pm="."><plain>Among 5 patients receiving VPA + ATRA from the start, none responded according to IWG criteria, but 1 patient with sAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> achieved a marked reduction in peripheral and marrow blasts </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, VPA is of therapeutic benefit for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and ATRA may be effective when added later </plain></SENT>
</text></document>